April 24, 2025
Siren Biotechnology at UCSF is developing the first universal AAV-based gene therapy for solid tumors, starting with brain cancers like high-grade gliomas. To fund its upcoming first-in-human clinical trial, Siren launched a community investment round via Wefunder, seeking $50,000–$5 million. Its lead therapy, SRN-101, combines gene therapy with cytokine immunotherapy and has received FDA Orphan Drug and Rare Pediatric Disease designations. Backed by $28M in VC funding and key partnerships, Siren is accelerating toward clinical trials.
The article highlights Dr. Khasraw briefly, saying that he has been named a new member of Siren’s Clinical and Scientific Advisory Board, to help guide trial development and strategy.
Read the full article here.